Trial · NCT03118986
RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
NCT03118986, Phase 2, Completed, The Hospital for Sick Children
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy. Trials, record NCT03118986. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03118986
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
- NCT number
- NCT03118986
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 161 participants, actual
- Lead sponsor
- The Hospital for Sick Children
- Conditions
- Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology
- Interventions
- Olanzapine, Placebo Oral Tablet
- First posted
- 2017-04-18
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of chemotherapy-induced vomiting (CIV) control (complete plus partial control) | up to 8 days | Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during the phase. Partial CIV is defined as no more than 2 vomits or retches during any 24-hour period. |
| Primary | Rate of CIV control during the acute phase | up to 8 days | Partial control is defined as no more than two vomits or retches during any 24-hr period |
| Secondary | complete and partial CINV control | up to 1 month | Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase, Partial control is defined as no more than two vomits or retches during any 24-hr period |
| Secondary | Safety profile of olanzapine based on toxicities | up to 1 month | Based on descriptive statistics on reported toxicities. |
| Secondary | Safety profile of olanzapine based on weight | up to 1 month | Based on descriptive statistics on reported body weight |
| Secondary | Safety profile of olanzapine based on Pediatric Adverse Event Rating Scale (PAERs) | up to 1 month | Based on descriptive statistics on reported PAERs, will describe the most reported and most bothersome adverse events reported in the PAERs questionnaire. |
| Secondary | Safety profile of olanzapine based on prolactin | up to 1 month | Based on descriptive statistics on reported prolactin, will report incidence of abnormal prolactin values comparing the two arms |
| Secondary | Safety profile of olanzapine based on amylase | up to 1 month | Based on descriptive statistics on reported amylase, will report incidence of abnormal amylase values comparing the two arms |
| Secondary | Safety profile of olanzapine based on creatine phophotase | up to 1 month | Based on descriptive statistics on reported creatine phophotase, will report incidence of abnormal creatine phophotase values comparing the two arms |
| Secondary | Safety profile of olanzapine based on triglycerides | up to 1 month | Based on descriptive statistics on reported triglycerides, will report incidence of abnormal triglyceride values comparing the two arms |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 16945043 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03118986
GET https://conductscience.org/api/trials/v1/NCT03118986/registered